Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: kurozumi s. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Sagara Y, et al. Among authors: kurozumi s. Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3. Breast Cancer Res Treat. 2018. PMID: 29971625 Clinical Trial.
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.
Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H. Kurozumi S, et al. Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18. Breast Cancer Res Treat. 2016. PMID: 27318853 Free PMC article.
Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H. Kurozumi S, et al. PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018. PLoS One. 2018. PMID: 30080878 Free PMC article.
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Katayama A, Miligy IM, Shiino S, Toss MS, Eldib K, Kurozumi S, Quinn CM, Badr N, Murray C, Provenzano E, Callagy G, Martyn C, Millican-Slater R, Purdie C, Purnell D, Pinder SE, Oyama T, Shaaban AM, Ellis I, Lee AHS, Rakha EA. Katayama A, et al. Among authors: kurozumi s. Mod Pathol. 2021 Jul;34(7):1271-1281. doi: 10.1038/s41379-021-00738-5. Epub 2021 Feb 1. Mod Pathol. 2021. PMID: 33526875 Free PMC article.
138 results